Original Article

Striatal histamine mechanism in the pathogenesis of restless legs syndrome

Yuan-Yang Lai1,*, Kung-Chiao Hsieh2, Yu-Hsuan Cheng1, Keng-Tee Chew2, Darian Nguyen1, Lalini Ramanathan1 and Jerome M. Siegel1,2

1Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA and 2Veterans Administration Greater Los Angeles HealthCare System (VAGLAHS), Sepulveda, Los Angeles, CA

*Corresponding author. Yuan-Yang Lai, Neurobiology Research, VAGLAHS Sepulveda, 16111 Plummer Street, North Hills, CA 91343. Email: yylai@ucla.edu.

This work was conducted at VAGLAHS Sepulveda, 16111 Plummer Street, North Hills, CA 91343.

Abstract

Study Objectives: Restless legs syndrome (RLS) has been hypothesized to be generated by abnormal striatal dopamine transmission. Dopaminergic drugs are effective for the treatment of RLS. However, long-term use of dopaminergic drugs causes adverse effects. We used iron-deficient (ID) and iron-replacement (IR) rats to address the neuropathology of RLS and to determine if a histamine H3 receptor (H3R) antagonist might be a useful treatment. Histamine H3R antagonists have been shown to decrease motor activity.

Methods: Control and ID rats were surgically implanted with electrodes for polysomnographic recording. After 3 days of baseline polysomnographic recordings, rats were systemically injected with the H3R agonist, α-methylhistamine, and antagonist, thioperamide. Recordings were continued after drug injection. Striatal H3R levels from control, ID, and IR rats were determined by western blots. Blood from control, ID, and IR rats was collected for the measurement of hematocrit levels.

Results: α-Methylhistamine and thioperamide increased and decreased motor activity, respectively, in control rats. In ID rats, α-methylhistamine had no effect on motor activity, whereas thioperamide decreased periodic leg movement (PLM) in sleep. Sleep–wake states were not significantly altered under any conditions. Striatal H3R levels were highest in ID rats, moderate to low in IR rats, and lowest in control rats. Striatal H3R levels were also found to positively and negatively correlate with PLM in sleep and hematocrit levels, respectively.

Conclusions: A striatal histamine mechanism may be involved in ID anemia-induced RLS. Histamine H3R antagonists may be useful for the treatment of RLS.

Key words: animal models; periodic leg movements; movement disorders; neuropharmacology; restless legs syndrome; pharmacology

Statement of Significance

Restless legs syndrome (RLS) affects 5%–10% of the population. Though dopamine drugs are the first line and effective in the treatment of RLS, they cause adverse effects with long-term use. We used the iron-deficient (ID) rat, an animal model of RLS, to further explore the neural mechanisms that underlies the neuropathology of RLS, and test potential drug treatments for RLS. We found that overexpression of striatal histamine H3 receptors (H3R) may participate in the generation of RLS. We also found that the H3R antagonist, thioperamide, can reverse motor hyperactivity without changing sleep time in ID rats. Thus, H3R antagonists may have the potential for the treatment of RLS.
Introduction

State-dependent changes in motor activity across the sleep–wake cycle have been well documented. Motor activity appears as high muscle tone accompanied by phasic activity during waking. During slow-wave sleep (SWS), muscle tone is relatively low with little variation. During rapid eye movement (REM) sleep, muscle atonia, interrupted by muscle twitches occurs. Periodic leg movement (PLM) in humans is defined as regular, repetitive extensions of the great toe and dorsiflexion of the ankle, knee, and hip at 10- to 90-second intervals. PLM occurs in all sleep–wake states but most prominently in SWS. PLM can occur in all age groups and affects 5%–10% of the population. PLM has been reported in patients with restless legs syndrome (RLS; also known as Willis–Ekborn disease), REM sleep behavior disorder, narcolepsy, neurodegenerative diseases, iron deficiency (ID) anemia, end-stage renal disease, peripheral neuropathy, and depression [1–8]. PLM is also frequently reported in pregnant women [9], children with attention deficit hyperactivity disorder [10], and people taking antidepressants [11].

Dopaminergic drugs are effective for the treatment of RLS and PLM disorder. However, they cause adverse effects [12–15], such as an increase in severity of RLS symptoms (augmentation), compulsive eating, nausea, insomnia, and dizziness after long-term use. Thus, it is critical that alternative drugs be investigated, using an animal model, for the treatment of RLS. However, the subjective uncomfortable and/or painful sensations made it difficult to develop an animal model of RLS. On the other hand, more than 80% of RLS patients have PLM either in wake or in sleep [16, 17]. The observable motor event, the change in sleep patterns, and the response to the therapeutic drug can be observed in animals. Based on such observations, we have developed an animal model of RLS, the ID rat [18]. Our previous studies showed that ID rats exhibit excessive sleepiness in the active (dark) phase [19], a symptom resembling daytime sleepiness in RLS patients. Furthermore, ID rats express a circadian pattern of motor hyperactivity and a skewed distribution of inter-leg movement intervals, similar to symptoms observed in RLS and PLM disorder patients [19]. ID rats also have abnormal striatal dopamine transmission and respond positively to dopaminergic drugs [18]. Changes in sleep patterns have been reported in ID mice, with an increase in wake during the last 4 hours of the active phase, indicating a delayed sleep onset [20]. ID rats show similar symptoms and similar neuropathology to human RLS, and have a positive response to therapeutic drugs useful for the treatment of RLS [18, 19]. Thus, the ID rat can serve as an ideal animal model of RLS.

Histamine H3 receptor (H3R) mechanisms have been shown to be involved in the regulation of motor activity. Animal studies show that thioperamide, a H3R antagonist, decreases stimulant-induced motor activity, such as walking, running, and climbing in mice [21, 22]. We hypothesized that H3R may be involved in the generation of the motor component of RLS and thioperamide may be capable of reversing motor hyperactivity. In this study, we used ID rats to further investigate the neuropathology of RLS/PLM disorder and to test the efficacy of thioperamide in the treatment of RLS/PLM disorder.

Methods

All procedures were approved by the Institutional Animal Care and Use Committee (IACUC), the VA Greater Los Angeles Healthcare System.

Development of ID rat

Sprague-Dawley weanling rats (21 days old) were used to develop the control and ID rat, as described in our previous study [18]. The weanling rats were purchased from Charles River Laboratory, and then, divided into two groups, control and ID. Control rats were fed a standard rodent diet containing 35 ppm iron, while ID rats were fed a rodent diet containing 4 ppm iron (TD.80396, Harlan Teklad Lab) for 2 months.

Surgery for electrode implantation

Rats were implanted with electrodes for EEG and EMG recordings. Under isoflurane (1.5%) anesthesia, three jewelers’ screws were implanted over the cortex for cortical EEG recording. Flexible multi-stranded stainless steel wires (7935, A-M Systems, Carlsborg, WA) were inserted into the nuchal and hindlimb musculature bilaterally and routed subcutaneously to the skull for EMG recording. Wires from all electrodes were soldered to a 14-pin Amphenol strip connector and encased in an acrylic head plug.

Sleep and motor activity recording in the control, ID, and iron-replacement rat

Animals were allowed to recover from surgery for at least 7 days before being used for experiments. Animals were individually housed in a sound-attenuated chamber under a 12:12 light–dark cycle. Electrophysiological signals were collected and amplified through a polygraph (Model 15LT or Model 78E, Grass, MA), and then digitized and recorded via a Micro 1401 (Cambridge Electronics Design, Cambridge, UK). Sleep and phasic leg jerks in wake and in sleep were visually scored offline with a script in Spike2 (Cambridge Electronics Design). Infrared cameras were used for video recordings. Video images were captured digitally through a four-channel surveillance video recorder card (Q-See QSPDVR04; RapidOS, New Taipei City, Taiwan). Video was recorded continuously with time stamps matched to polysomnographic recordings.

After 3 days of baseline sleep and motor activity recordings, seven each control and ID rats were injected with drugs (see section below). The rest of 16 ID rats were divided into four groups, with each group fed with standard rodent diet (iron replacement) for 1 (IR1), 2 (IR2), 3 (IR3), and 4 (IR4) weeks. Sleep and motor activity recordings in IR rats were resumed on day 6 post-standard rodent diet feeding for 2 days continuously each week, for an additional 3 weeks. The number of rats for each IRs group is 4.

Drug injection experiment

After 3-day baseline sleep and motor activity recordings, control and ID rats were intraperitoneally injected with test drugs, saline, or 30% dimethyl sulfoxide (DMSO) in saline (DMSO–saline) at Zeitgeber Time (ZT) 2. Drugs used for the experiment included α-methylhistamine (α-MH, Tocris Bioscience), a histamine H3R agonist, and thioperamide (Tocris Bioscience), a H3R antagonist. The concentration of each drug was 1, 3, and 6 mg/kg for both α-MH and thioperamide. α-MH was dissolved in Ringer’s saline, whereas thioperamide was dissolved in 30% DMSO and then diluted with Ringer’s saline, immediately before injection. Thus,
the concentration of DMSO was 1%, 3%, and 6% for 1, 3, and 6 mg/kg thioperamide injection solution, respectively. Different doses of each test drug were delivered into the same animal 2 days apart, to avoid any residual effects from the previous injection. Injections of different test drugs were performed 1 week apart.

One week after completing the drug injection experiment, control and ID rats were sacrificed at 10 am. IR rats were sacrificed at 10 am on days 7 (IR1), 14 (IR2), 21 (IR3), and 28 (IR4), post-standard rodent diet feeding. All animals were deeply anesthetized with isoflurane and their brains removed. The striatum was dissected on ice and stored at −80 °C for subsequent use in western blots.

**Hematocrit measurement**

Blood was collected from the lateral tail vein after isoflurane anesthesia and immediately before sacrificing the animal, transferred into a heparinized hematocrit capillary, and centrifuged at 12 000 × g for 3 minutes in a hematocrit centrifuge (BD Clay Adams, 420563). Hematocrit levels were calculated by measuring the length of the red blood cell layer against the total blood layer.

**Western blot experiment**

Striatal tissues were taken from four animals in each control and experimental group. Striatal tissues were separately sonicated in lysis buffer (50 mM Tris, 5 mM ethylenediaminetetraacetic acid, 30% IGEPAL NP-40, 10% Na deoxycholate, and 1% sodium dodecyl sulfate, pH 7.5) and protease inhibitor tablet (Roche, 4693124), and then centrifuged at 10 000 × g for 20 minutes at 4 °C. Protein concentration of the supernatant was determined using the DC protein assay kit (Bio-Rad, 500-0112) and read at 750 nm in an Emax Precision microplate reader (Molecular Devices) using the Softmax program. Ten micrograms of striatal proteins were loaded on a 10% mini-protean TGX precast gel (Bio-Rad, 456-307) and transferred into a heparinized hematocrit capillary, and centrifuged at 12 000 × g for 3 minutes at RT. Membranes were washed in Tris-buffered saline with Tween (TBST: 20 mM Tris, 150 mM NaCl, 0.1% Tween), and then blocked in TBST containing 5% non-fat dry milk for 1 hour at RT. Membranes were subsequently incubated with rabbit anti-histamine H3R (1:4000, Millipore, AB15860) and mouse anti-actin (1:10 000, Millipore, MAB1501R) overnight at 4 °C, goat anti-rabbit IgG conjugated with HRP (1:10 000, Jackson ImmunoResearch Lab, 111-035-144) and goat anti-mouse IgG conjugated with HRP (1:10 000, Jackson ImmunoResearch Lab, 715-035-140) for 1 hour, and West Femto (1:80, goat anti-mouse IgG conjugated with HRP (1:10 000, Jackson Immunores Lab, 111-035-144) and mouse anti-actin (1:10 000, Millipore, MAB15860) for 1 hour, and West Femto (1:80; Thermo Scientific, 34094) for 5 minutes at RT. H3R (48.6 KDa) and β-actin (42 KDa) were detected and visualized using a ChemiDoc XRS+ system (Bio-Rad). Membranes were washed three times in TBST between incubations. β-Actin was used as an internal normalizer. The optical densities of the H3R and β-actin bands were measured using a Quantity One 1-D analysis software (Bio-Rad).

Striatal proteins from control, ID, and IR1-IR4 rats were analyzed simultaneously on the same gels and blots.

**Data analysis**

The CED 1401 Spike 2 program was used to analyze EEG power spectra, as well as to detect and score phasic muscle activity during quiet wake and sleep. Periodic leg movements in quiet wake (PLMW) and in SWS (PLMS) were analyzed by adapting the criteria outlined by the World Association of Sleep Medicine [23, 24] and described in our previous study [18]. In brief, phasic motor events in the leg satisfying the following criteria were counted as PLM: (1) the amplitude was twice that of the tonic background activity, (2) the duration ranged between 0.2 and 5 seconds, (3) the interval between jerks was between 10 and 90 seconds, and (4) at least four consecutive jerks fulfilled the three criteria described above. The PLMS event ended either when the animal awakened from sleep or the inter-leg movement-interval was longer than 90 seconds. Phasic motor events in sleep, which did not meet the criteria of PLMS, were counted as isolated leg movements (ILM). The index of PLM in quiet wake (PLMWI) and in SWS (PLMSI) was calculated as the total number of periodic motor movements divided by total time in quiet wake or in SWS, over 2 or 8 hours. Similarly, the index of ILM in sleep (ILMSI) was calculated as the total number of ILM in sleep divided by total time in sleep, over 2 or 8 hours.

To determine long-term and short-term effects of test drugs on sleep and motor activity, the total time in wake, SWS, and REM sleep, as well as PLMWI, PLMSI, and ILMSI were determined in 2-hour epochs (short term) or total 8 hours (long term) after saline/DMSO–saline and H3R agonist and antagonist injections. One-way analysis of variance (ANOVA) with replicated measures followed by Bonferroni’s post hoc and t-tests were used for statistical analysis.

**Results**

**Effect of α-MH and thioperamide on sleep and motor activity in control rats**

α-MH, at any dose (1, 3, and 6 mg/kg), injected intraperitoneally into control rats produced no change in wake, SWS, or REM sleep time when averaged over the 8 hours of recording post-injection (Figure 1, left panel) or scored over 2-hour epochs post-injection in the control rat. In contrast, α-MH injection produced dose-dependent increase in PLM in sleep (Figure 2, left panel, p < 0.001, df = 5, ANOVA). PLM in sleep significantly increased after α-MH at 3 mg/kg (Figure 2, left panel) and 6 mg/kg (Figure 2, left panel) injection when averaged over the 8 hours of recording. α-MH at 1 mg/kg injected into control rats had no effect on motor activity (Figure 2, left panel) over the 8 hours of recording. Increased PLM in sleep were observed starting hour 3 post-α-MH injection (Figure 3, left panel). Isolated leg movements in sleep were not changed by α-MH injection at any dose and at any time period (Figure 2, left panel; Figure 3, right panel). Similar to α-MH injection, systemic injection of thioperamide did not change time in wake, SWS, and REM sleep (Figure 1, left panel), nor the number of ILM in sleep (Figure 2, left panel; Figure 3, right panel) at any time after injection. However, thioperamide injections produced dose-dependent decreases in the number of PLM in sleep at hours 3 and 4 post-injection (Figure 3, left panel). Saline or DMSO–saline injection produced no changes in wake and sleep time (Figure 1, left panel), as well as PLM (Figure 2, left panel) and ILM (Figure 2, left panel; Figure 3, right panel) in sleep. Neither DMSO–saline nor DMSO–saline–thioperamide injection changed motor behaviors, such as scratching, grooming, climbing, and running.
Effect of histamine H3R agonist and antagonist on sleep and motor activity in ID rats

Similar to control rats, α-MH injection in ID rats produced no significant change in sleep–wake states (Figure 1, right panel) when averaged over the 8 hours post-injection period, or even when scored in 2-hour epochs. In contrast to control rats, α-MH injection in ID rats produced no change in the number of PLM (Figure 2, right panel) in sleep, even when scored in 2-hour epochs (Figure 4, left panel). Though an increase in PLM in quiet wake was found after α-MH injection in ID rats, the change was not significant (Figures 2 and 4, right panel). Similar to α-MH injection, systemic injection of thioperamide into ID rats produced no changes in total time spent in wake or sleep over 8 hours (Figure 1, right panel), or 2-hour epochs after injection. Isolated leg movements in sleep were not changed by thioperamide injection (Figure 2, right panel). However, PLM in sleep dose dependently decreased with thioperamide injection in rats (p < 0.05, df = 5, ANOVA). This effect was not only seen during the 8-hour post-injection period (Figure 2, right panel), but also in the 2-hour epoch post-injection (Figure 4, left panel). Though PLM in wake was also decreased by thioperamide injection in ID rats, the change was not significant (Figures 2 and 4, right panel).

Hematocrit levels and motor activity in IR rats, as well as striatal levels of H3R in control, ID, and IR rats

Consistent with our previously reported data [18], hematocrit levels and PLM in sleep were normalized after ID rats were fed standard rodent diet (Figure 5). The present study showed that striatal H3R levels are highest in ID rats, moderate to low in IRs rats, and lowest in control rats (Figure 5). Statistical analysis found that striatal levels of H3R are positively correlated with PLMs in sleep (R² = 0.6, p < 0.01, n = 24, Pearson correlation test).
and negatively correlated with hematocrit levels ($R^2 = −0.65$, $p <0.01$, $n = 24$, Pearson correlation test).

**Discussion**

Dopaminergic mechanisms have been hypothesized to be involved in the pathophysiology of RLS. An increase in tyrosine hydroxylase (TH) and phosphorylated TH in the substantia nigra (SN) and an increase in phosphorylated TH and a decrease in dopamine D2 receptors in the putamen have been reported in RLS patients [25]. A decrease [26] or an increase [27] in striatal levels of dopamine transporter have also been demonstrated in RLS patients. ID rats, an animal model of RLS [18], also showed an increase in TH and phosphorylated TH in the SN [25], as well as an increase in dopamine transporter in the striatum [18]. Although symptoms of RLS and PLM disorder patients can be relieved with iron therapy [28] and disorders of RLS-like behaviors in ID rats can be corrected with iron replacement [18], the neural abnormality of the SN cannot be reversed in ID rats fed with high iron diet [25]. Thus, other mechanisms in the striatum, which affect dopamine transmission, may be involved in the generation of motor hyperactivity.

Clinical studies showed that 24% of ID anemia patients have RLS [1], indicating that systemic anemia does not always produce RLS. Allen et al. [1] reported that plasma levels of ferritin and hemoglobin are not different in idiopathic RLS patients and controls. On the other hand, brain levels of iron and ferritin were low and transferrin levels were high in idiopathic RLS patients [29]. A decrease in the brain level of iron and ferritin and an increase in the brain level of transferrin has also been found in ID weanling male Sprague-Dawley rats [30] fed with a low-iron diet for 4–6 weeks [31]. In addition, a decrease in striatal levels of dopamine D1 (D1) and dopamine D2 (D2) receptors was also found in ID rats [32]. Though brain levels of iron, ferritin, and...
Histamine H₃ receptor mechanisms have been shown to be involved in the regulation of motor activity. Animal studies showed that both α-MH and thioperamide have no effect on spontaneous motor activity during wake in mice [21] or in rats [33]. Systemic injection of α-MH produces no effect on stimulated motor activity in mice [21] or in rats [33]. However, thioperamide injection decreases stimulant-induced motor activities, as well as walking, running, and climbing activities in mice [21, 22]. Consistent with these findings, our present study showed that neither α-MH nor thioperamide changes motor activity in wake. However, we found that α-MH and thioperamide increases and decreases motor activity in sleep, respectively, which was not reported by Clapham and Kilpartrick [21] or Nosál et al. [22]. Based on our findings, we then examined the effect of these drugs on motor activity in ID rats. In contrast to control rats, systemic application of α-MH into ID rats failed to change PLM in sleep. This may be due to a change in neurotransmission in the striatum of ID rats. Iron deficiency not only changes the dopaminergic system in the SN and striatum [18, 25], but also alters the GABAergic system. Anderson et al. [34] reported that GABA uptake decreases in the striatum in ID rats. The decrease in GABA uptake results in an increase in GABA levels in the synapse and consequently decreases striatal neuronal activity. The decreased striatal activity and/or neurodegeneration of the striatopallidal neurons have been shown to increase motor activity in mice [35]. However, PLM in sleep was dramatically suppressed by all doses of thioperamide injection in ID rats. The efficacy of the thioperamide suppressive effect on motor activity in sleep and in wake in ID rats is comparable to that of pramipexole, shown in our previous study [18], a drug commonly used to treat RLS.

Mechanisms underlying motor hypoactivity caused by H₃R antagonists have not been documented. Our present study showed that striatal H₃R levels are positively correlated with PLM in sleep. This led us to speculate that over expression of H₃R in the striatum may cause motor hyperactivity. The histamine H₃R is a presynaptic and a postsynaptic receptor. At presynaptic terminals, H₃R not only acts as a heteroreceptor, which suppresses transmitter release [36] and modulates striatal medium spiny neuron (MSN) activity [37], but also forms with adenosine A₃ receptor (A₃R) as the heteromers [38]. Activation of H₃R increases the A₃R activity-induced cAMP formation [38], and causes neurotransmitter release [39]. Adenosine A₃R has been shown to increase glutamatergic release from corticostral terminal [40, 41]. Thus, the increased H₃R, as seen in our present study, as well as the increased A₃R in ID rats [42] may corparate into the heteromers and contribute to the increase in glutamate release from corticostral terminals, result in PLM generation [43]. Yepes et al. [43] reported that pramipexole, drug commonly used for the treatment of RLS, suppresses cortical stimulation-induced glutamate release. H₃R has also been shown to interact with other receptors at the postsynaptic level. Ferrada et al. [44] showed that a strong interaction between H₃R and dopamine D₂ receptors exists at the postsynaptic striatal cell membrane level. Using radioligand binding technique, they found that H₃R agonist decreases the affinity of postsynaptic dopamine D₂ receptor for its agonists in the striatum. Inactivation or neurodegeneration of striatonigral D₂ receptor containing MSN (D1-MSN) and striatopallidal D₂ receptor containing MSN (D2-MSN) decreases and increases motor activity in mice, respectively [35]. Neuroimaging studies showed that the density of striatal postsynaptic D₂ receptors in RLS patients is either not changed [45] or decreased [46]. We hypothesize that overexpression of H₃R in the striatum, as seen in ID rats, causes an increase in glutamate release from the corticostral terminals by enhancing A₃R activity and a decrease in the ability of dopamine D₂ receptors to bind dopamine agonists in the striatum. Application of H₃R antagonists may thus decrease A₃R activity and restore the function of dopamine D₂ receptors in the striatum and improve motor hyperactivity in sleep, as seen in the present study. In addition, the effect of thioperamide on motor activity may also be mediated through the SN pars reticulata (SNR). Activation of H₃R by application of imetit, a H₃R agonist, in the SNR decreases GABAergic neuronal activity [47]. Inactivation of the SNR by muscimol infusion has been shown to cause hyposomnia and PLM-like activity in wake and increase PLM-like activity in sleep [48]. Therefore, application of thioperamide increases SNR GABAergic neuronal activity and reduces RLS-like activity in ID rats. However, H₃R control of motor component of RLS-like activity in ID rats mediated through peripheral structures, such as skin, muscle, and spinal cord cannot be ruled out. Histamine H₃Rs have been found in peripheral sensory fibers, dorsal root ganglia, and spinal dorsal horn [49]. These H₃Rs act as heteroreceptors and suppress GABA and/or glycine release, resulting in sensorimotor hyperactivity. Further study is needed to address whether an upregulation of H₃R occurred in the spinal cord and peripheral tissues in ID animals.

Using high-performance liquid chromatography analysis technique, Sakurai et al. [50] showed that the half-life of thioperamide in the plasma is 26.9 minutes in male Wistar rats.
neuropathology of RLS and PLM disorder. Iron therapy not only reverses RLS-like symptoms but also decreases striatal H3R levels. H3R antagonist, thioperamide, produces no change in sleep–wake states, but suppresses motor hyperactivity in sleep in ID rats. Thus, H3R antagonists may have potential for the treatment of RLS and PLM disorder.

**Funding**

This work supported by the Restless Legs Syndrome Foundation (Y.-Y.L.), the National Institute of Health grants, NS082242 (Y.-Y.L) and DA034748 (J.M.S.), and the Department of Veterans Affairs.

Conflict of interest statement. None declared.

**References**

1. Allen RP, et al. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. *Am J Hematol.* 2013;88(4):261–264.
2. Bhalsing K, et al. Prevalence and profile of restless legs syndrome in Parkinson’s disease and other neurodegenerative disorders: a case-control study. *Parkinsonism Relat Disord.* 2013;19(4):426–430.
3. Iannaccone S, et al. Evidence of peripheral axonal neuropathy in primary restless legs syndrome. *Mov Disord.* 1995;10(1):2–9.
4. Lee HB, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. *J Neuropsychiatry Clin Neurosci.* 2008;20(1):101–105.
5. Piazzì G, et al. Periodic leg movements during sleep in narcoleptic patients with or without restless legs syndrome. *J Sleep Res.* 2012;21(2):155–162.
6. Polydefkis M, et al. Subclinical sensory neuropathy in late-onset restless legs syndrome. *Neurology.* 2000;55(8):1115–1121.
7. Walters AS, et al. A preliminary look at the percentage of patients with restless legs syndrome who also have Parkinson disease, essential tremor or Tourette syndrome in a single practice. *J Sleep Res.* 2003;12(4):343–345.
8. Winkelman JW, et al. Restless legs syndrome in end-stage renal disease. *Am J Kidney Dis.* 1996;28(3):372–378.
9. Lee KA, et al. Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron. *J Womens Health Gend Based Med.* 2001;10(4):335–341.
10. Crabtree VM, et al. Periodic limb movement disorder of sleep in children. *J Sleep Res.* 2003;12(1):73–81.
11. Yang C, et al. Antidepressants and periodic leg movements of sleep. *Biol Psychiatry.* 2005;58(6):510–514.
12. García-Borreguero D, et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. *Mov Disord.* 2007;22(Suppl. 18):S476–S484.
13. Godau J, et al. Rotigotine in the long-term treatment of severe RLS with augmentation: a series of 28 cases. *Sleep.* 2012;35(8):1010–1015.
14. Silber MH, et al. Pramipexole in the management of restless legs syndrome: an extended study. *Sleep.* 2003;26(7):819–821.
15. von Scheele C, et al. Long-term effect of dopaminergic drugs in restless legs. *A 2-year follow-up.* *Arch Neurol.* 1990;47(11):1223–1224.
16. Montplaisir J, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12(1):61–65.
17. Montplaisir J, et al. Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord. 1998;13(2):324–329.
18. Lai YY, et al. Motor hyperactivity of the iron-deficient rat—an animal model of restless legs syndrome. Mov Disord. 2017;32(12):1687–1693.
19. Lai YY, et al. Reply: the iron-deficient rat as a model of restless legs syndrome: was anything lost in translation? Mov Disord. 2018;33(1):182–183.
20. Dean T Jr, et al. The effects of dietary iron deprivation on murine circadian sleep architecture. Sleep Med. 2006;7(8):634–640.
21. Clapham J, et al. Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol. 1994;259(2):107–114.
22. Nosál R, et al. Central histaminergic H3-receptors and locomotor activity. Inflamm Res. 2001;50(Suppl. 2):S76–S77.
23. Allen RP, et al.; International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15(8):860–873.
24. Zucconi M, et al.; International Restless Legs Syndrome Study Group (IRLSSG). The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med. 2006;7(2):175–183.
25. Connor JR, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain. 2009;132(Pt 9):2403–2412.
26. Earley CJ, et al. The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep. 2011;34(3):341–347.
27. Kim KW, et al. Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients. Eur J Neurosci. 2012;39(9):1213–1218.
28. Aurora RN, et al.; American Academy of Sleep Medicine. The treatment of restless legs syndrome and periodic limb movement disorder in adults—an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039–1062.
29. Mizuno S, et al. CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res. 2005;14(1):43–47.
30. Erikson KM, et al. Regional brain iron, ferritin and transferrin concentrations during iron deficiency and iron repletion in developing rats. J Nutr. 1997;127(10):2030–2038.
31. Han J, et al. Gene expression of transferrin and transferrin receptor in brains of control vs. iron-deficient rats. Nutr Neurosci. 2003;6(1):1–10.
32. Erikson KM, et al. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacol Biochem Behav. 2001;69(3–4):409–418.
33. Pillot C, et al. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J Neurosci. 2002;22(16):7272–7280.
34. Anderson JG, et al. Brain manganese accumulation is inversely related to gamma-amino butyric acid uptake in male and female rats. Toxicol Sci. 2007;95(1):188–195.
35. Bateup HS, et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci USA. 2010;107(33):14845–14850.
36. Molina-Hernández A, et al. Histamine H3 receptor activation inhibits glutamate release from rat striatal synaptosomes. Neuropharmacology. 2001;41(8):928–934.
37. Ellender TJ, et al. Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine. J Neurosci. 2011;31(43):15340–15351.
38. Márquez-Gómez R, et al. Functional histamine H3 and adenosine A2A receptor heteromers in recombinant cells and rat striatum. Pharmacol Res. 2018;129:515–525.
39. Costa WS, Yu SC, Liewald JF, et al. Fast cAMP modulation neurotransmission via neuropeptide signals and vesicle loading. Curr Biol. 2017;27:495–507.
40. Ciruela F, et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1–A2A receptor heteromers. J Neurosci. 2006;26(7):2080–2087.
41. Popoli P, et al. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol. 1995;287(2):215–217.
42. Quiroz C, et al. Up-regulation of striatal adenosine A2A receptors with iron deficiency in rats: effects on locomotion and cortico-striatal neurotransmission. Exp Neurol. 2010;224(1):292–298.
43. Yepes G, et al. Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Ann Neurol. 2017;82(6):951–960.
44. Ferrada C, et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology. 2008;55(2):190–197.
45. Eisensehr I, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology. 2001;57(7):1307–1309.
46. Michaud M, et al. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurool. 2002;249(2):164–170.
47. Zhou FW, et al. Opposite functions of histamine H1 and H2 receptors and H3 receptor in substantia nigra pars reticulata. J Neurophysiol. 2006;96(3):1581–1591.
48. Lai YY, et al. Role of the substantia nigra in the control of sleep and motor activity in sleep. Sleep. 2009;32(Suppl. A302).
49. Cannon KE, et al. Immunohistochemical localization of histamine H3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinoceceptive targets. Pain. 2007;129(1–2):76–92.
50. Sakurai E, et al. The disposition of thioperamide, a histamine H3 receptor antagonist, in rats. J Pharm Pharmacol. 1994;46(3):209–212.
51. Eisenreich W, et al. Pramipexole extended release: a novel treatment option in Parkinson’s disease. Parkinsons Dis. 2010;2010:612619.
52. Allen RP, et al. Anti-histamine and benzodiazepines exacerbate daytime restless legs syndrome (RLS) symptoms. Sleep. 2005;28(Suppl.):A279.
53. Tanda G, et al. Cocaine-like neurochemical effects of antihistaminic medications. J Neurochem. 2008;106(1):147–157.
54. Tanaka T, et al. Diphenhydramine overdose mimicking serotonin syndrome. Psychiatry Clin Neurosci. 2011;65(5):534.
55. Jacob BL, et al. 5-HT and motor control: a hypothesis. TINS. 1995;16:342–356.
56. O’Sullivan RL, et al. H2 antagonists, restless leg syndrome, and movement disorders. Psychosomatics. 1993;34(6):530–532.
57. Monti JM, et al. Effects of selective activation or blockade of the histamine H3 receptor on sleep and wakefulness. Eur J Pharmacol. 1991;205(3):283–287.
58. Kalivas PW. Histamine-induced arousal in the conscious and pentobarbital-pretreated rat. J Pharmacol Exp Ther. 1982;222(1):37–42.